目前使用金属离子结合抑制剂准金属β-乳糖酶的战略
Jessica L Ortega-Balleza1,2, Lenci K Vázquez-Jiménez1,2, Eyra Ortiz-Pérez1
1Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
Molecules (Basel, Switzerland)
|August 29, 2024
概括
抗菌素耐药性 (AMR) 是一种由多药耐药细菌驱动的全球威胁. 本综述探讨了新型金属β-乳糖酶 (MBL) 抑制剂,该抑制剂可化离子,用于对抗耐药性感染.
科学领域:
- 微生物学 微生物学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗菌素耐药性 (AMR) 构成了全球重大健康挑战.
- 多抗药性 (MDR) 细菌,特别是那些产生β-乳酸酶的细菌,是一个主要问题.
- 金属β-乳酸酶 (MBLs) 对关键的抗生素类别 - - 碳烯胺产生耐药性,并且不会被现有的药物抑制.
研究的目的:
- 审查目前设计针对MBL的抑制剂的策略.
- 分析这些新型抑制剂的作用机制.
- 通过MBL抑制提供对抗MDR细菌的见解.
主要方法:
- 关于MBL抑制剂的科学出版物的文献综述.
- 分析各种类型的抑制剂的化学结构和作用机制.
- 专注于结合策略及其有效性.
主要成果:
- MBL 抑制剂通常包含,硫醇或金属结合性碳酸盐.
- 双循环酸盐和像二林酸这样的化合物通过模仿中间体或化来表现出有希望的表现.
- 化是许多MBL抑制剂的关键机制.
结论:
- 开发有效的MBL抑制剂对于治疗由MDR细菌引起的感染至关重要.
- 专注于结合的策略为新治疗剂提供了有希望的途径.
- 对金属离子结合抑制剂的进一步研究对于解决AMR危机至关重要.
相关概念视频
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Enzyme Inhibition
78.1K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.1K
Antibiotic Selection
52.4K
Overview
52.4K
Extraction: Advanced Methods
433
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
433


